Skip to content
    KNSA
    Earnings call· Dec 2025(Q4 FY25)

    Kiniksa Pharmaceuticals International Q4 FY25 earnings call KNSA

    Feb 24, 2026 Source

    Executive summary

    Kiniksa Pharmaceuticals Q4 FY25 — ARCALYST Drives Strong Revenue Growth and Profitability, Pipeline Advances

    Kiniksa Pharmaceuticals delivered robust Q4 and full-year 2025 results, driven by strong ARCALYST revenue growth and expanding adoption in recurrent pericarditis. The company achieved profitability and significant cash generation, enabling continued investment in its commercial infrastructure and advancing its clinical pipeline with KPL-387 and KPL-1161. Management is focused on unlocking the next phase of ARCALYST growth through increased physician awareness and digital marketing, while also preparing for future market expansion with its pipeline assets.

    Highlights

    5

    • ARCALYST product revenue grew 65% year-over-year to $202.1 million in Q4 FY25 and 62% to $677.6 million for the full year 2025.

    • Net income was $14.2 million in Q4 FY25, compared to a net loss of $8.9 million in Q4 FY24, and $59 million for full year 2025.

    • ARCALYST collaboration profit grew 83% to $140 million in Q4 FY25 and 96% to $459 million for the full year 2025.

    • Ended FY25 with a strong cash position of $414.1 million, representing $170.4 million of net cash generation for the year.

    • KPL-387 Phase II portion of the clinical trial is on track for data readout in H2 2026, and KPL-1161 is expected to be in clinic by end of 2026.

    Concerns

    1

    • Q1 2026 is expected to face seasonal headwinds in the specialty drug sector associated with payer plan changes and co-pay resets.

    Guidance & targets

    4
    CategoryTargetConfidence
    ARCALYST Net Revenue
    $900 million - $920 million
    high materiality
    High
    KPL-387 Phase II Data Readout
    Second half of 2026
    high materiality
    High
    KPL-1161 Clinic Entry
    By the end of 2026
    medium materiality
    High
    KPL-387 Launch Timeline
    2028-2029 time frame
    high materiality
    Medium

    Segment performance

    1
    SegmentRevenueYoYQoQMargin
    ARCALYST
    ARCALYST continues to drive significant revenue growth and profitability, fueled by expanding adoption in recurrent pericarditis. The product has established strong commercial fundamentals, with increasing penetration into the target market and growing utilization earlier in the disease course. The 2025 ACC concise clinical guidance further supports its use as a second-line treatment.
    Product Revenue Q4 FY25: $202.1 millionProduct Revenue Growth YoY Q4 FY25: 65%Product Revenue Full Year FY25: $677.6 millionProduct Revenue Growth YoY Full Year FY25: 62%Collaboration Profit Q4 FY25: $140 millionCollaboration Profit Growth YoY Q4 FY25: 83%Collaboration Profit Full Year FY25: $459 millionCollaboration Profit Growth YoY Full Year FY25: 96%Total Prescribers: >4,150Repeat Prescribers (2+ patients): >1,200 (29% of total)Penetration into 2+ Recurrence Target Market: ~18% (up from 15% mid-2025 and 13% end-2024)Prescriptions for First Recurrence Patients: ~20% of total ARCALYST prescriptionsAverage Total Duration of Therapy: Approaching 3 yearsPayer Approval Rates: RobustPatient Adherence: Strong
    		————

    Operational metrics

    7
    Cash and Investments Balance
    $414.1 million
    End of FY25

    Company's cash position at the end of the fiscal year.

    Net Cash Generation
    $170.4 million
    Full Year FY25

    Amount of cash generated during the full fiscal year.

    Cash Flow Positive Outlook
    Expect to remain cash flow positive
    Annual basis

    Under current operating plan.

    Target Market Population (2+ recurrences)
    14,000
    End of FY25

    Estimated population of patients with two or more recurrent pericarditis episodes.

    Target Market Population (First recurrence)
    26,000
    Any given year

    Estimated population of patients experiencing their first recurrent pericarditis episode annually.

    KPL-387 Patient Preference
    75%
    Market research

    Market research data on patient preference for KPL-387's target product profile.

    KPL-387 HCP Prescription Likelihood
    >90%
    Market research

    Market research data on healthcare professional's likelihood to prescribe KPL-387.

    Industry KPIs

    9
    MetricValueDetails
    Launch access metricsRobust payer approval rates and strong patient adherence
    Pipeline read out calendarKPL-387 Phase II data
    Regulatory approvals filingsAffirmed Phase II pivotal for U.S. registration
    Peak long term sales guidanceBlockbuster status
    Therapeutic drug market share~18%%
    Prescription volume new starts>4,150prescribers
    Clinical trial efficacy safety dataRobust safety and efficacy data
    Collaboration milestone royalty revenue$459 millionUSD
    Cumulative patients uptake since launchThousandspatients

    Risks & headwinds

    1
    Seasonal headwinds in Q1Q1 2026

    Associated with payer plan changes and co-pay resets

    What to watch in Q1 FY26

    4

    ARCALYST Q1 Seasonal Headwinds Impact

    Next quarter
    CurrentQ1 2026 expected to face seasonal headwinds
    TargetQuantification of impact on ARCALYST sales

    Why it matters

    Seasonal headwinds can affect ARCALYST's sales trajectory and overall revenue performance in the short term.

    Historically, Q1 faces some seasonal headwinds in the specialty drug sector associated with payer plan changes and co-pay resets.

    Q&A highlights

    5

    What is the peak penetration for ARCALYST in the multiple recurrent setting, and how might KPL-387's potential approval affect this?

    Management has not commented on peak penetration but believes there is significant growth opportunity for ARCALYST, currently at 18% penetration in the 2+ recurrence market (14,000 patients). The first recurrence market (26,000 patients) represents an even larger opportunity. KPL-387 is designed to expand the market with monthly dosing and auto-injector potential, addressing key patient needs and preferences.

    “We announced we're around 18% penetrated into the target population of patients with 2 or more recurrences. That's a 14,000 population at the end of 2025. And that's without taking into account those patients that are earlier on in the disease on their first recurrence, which is a much larger group of patients, around 26,000 patients in any given year.”

    asked by Nicholas Lorusso · answered by Ross Moat

    2 min read6 chapters

    Detailed Narrative

    01

    ARCALYST Commercial Performance and Growth Drivers

    ARCALYST demonstrated significant commercial success in 2025, with full-year net revenue reaching $677.6 million, a 62% increase over 2024. This growth was primarily driven by expanding adoption of IL-1 alpha and beta inhibition as a second-line treatment for recurrent pericarditis. The company has established a strong commercial foundation with an average total duration of therapy approaching 3 years, robust payer approval rates, and strong patient adherence. Penetration into the 2-plus recurrence target market increased to approximately 18% by the end of 2025, up from 13% at the end of 2024.

    02

    Strategic Investments and Future Growth Initiatives for ARCALYST

    Kiniksa has leveraged ARCALYST's profitability to make strategic investments in its commercial infrastructure and digital marketing efforts. In 2026, the focus is on driving further physician awareness of the 2025 ACC concise clinical guidance, which recommends IL-1 pathway inhibition as a second-line approach. The company is also advancing digital marketing initiatives, utilizing AI and machine learning for physician targeting, and exploring ways to expand the impact of pericardial disease centers, where ARCALYST prescription growth has outpaced other sites.

    03

    KPL-387 Development and Market Potential

    KPL-387, an internally discovered asset, is currently in the Phase II portion of a Phase II/III clinical trial for recurrent pericarditis, with data expected in the second half of 2026. This asset is designed to address key patient needs with potential monthly dosing via an auto-injector, aiming to expand penetration into the addressable market. Management believes KPL-387 could extend Kiniksa's leadership in the recurrent pericarditis market, with a target launch timeline in the 2028-2029 timeframe.

    04

    KPL-1161 Preclinical Progress

    Kiniksa also announced plans to advance KPL-1161, an Fc-modified IL-1 alpha and beta inhibitor, into clinical trials by the end of 2026. This asset represents another internally developed program aimed at further strengthening the company's IL-1 inhibition franchise and addressing unmet patient needs in debilitating diseases.

    05

    Financial Strength and Cash Flow Generation

    The company reported a strong financial position, ending 2025 with $414.1 million in cash, reflecting $170.4 million of net cash generation for the year. Kiniksa expects to remain cash flow positive on an annual basis under its current operating plan, providing flexibility for R&D investments, advancing its pipeline, and pursuing strategic business development opportunities.

    06

    Regulatory Interactions and Clinical Trial Design

    Kiniksa has had productive interactions with the FDA regarding KPL-387, affirming that the Phase II trial could be sufficient and pivotal for U.S. registration. The KPL-387 program is designed to support a broad label for recurrent pericarditis, similar to ARCALYST, treating patients regardless of prior therapy or number of recurrences. The company is always looking for opportunities to accelerate development while maintaining rigorous trial design.

    AI-generated summary of the company’s earnings call. Not investment advice.